- Conditions
- Trauma, Infection, Bone Fracture
- Interventions
- Imaging using 5-Aminolevulinic Acid (5-ALA) during surgery
- Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- pHLIP® ICG NIRF imaging
- Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Montvale, New Jersey • New York, New York
- Conditions
- Coronary Artery Disease
- Interventions
- ComboMap XT Guidewire, 'SPY' NIRF During CABG
- Device · Procedure
- Lead sponsor
- East Carolina University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Rectal Neoplasms, Colon Neoplasms, Diverticulitis
- Interventions
- Indocyanine Green, The SPY® Intraoperative Imaging System
- Device
- Lead sponsor
- Maimonides Medical Center
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Cholecystitis
- Interventions
- Stryker1688 Fluorescence imaging system
- Device
- Lead sponsor
- Stryker Endoscopy
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Annapolis, Maryland
- Conditions
- Biliary Stones, Cholangiocarcinoma, Intrahepatic, Biliary Stricture, Cholelithiasis, Choledocholithiasis
- Interventions
- Percutaneous cholangiopancreatoscopy
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Sarcoma
- Interventions
- Indocyanine green solution administered at 2.0mg/kg., Stryker SPY-PHI Imaging Device
- Drug · Device
- Lead sponsor
- Kurt Weiss
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cholelithiasis, Cholecystitis, Pancreatitis Biliary, Colic of Gallbladder Without Mention of Cholecystitis
- Interventions
- Indocyanine Green (ICG)
- Drug
- Lead sponsor
- Maimonides Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Extremity Lower Wounds
- Interventions
- SPY Intra-operative Angiography
- Combination Product
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer, Necrosis
- Interventions
- ICG microangiography
- Diagnostic Test
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Breast Cancer
- Interventions
- diffusion-weighted magnetic resonance imaging
- Procedure
- Lead sponsor
- American College of Radiology Imaging Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 4 more
- Conditions
- Trauma Injury
- Interventions
- Immunofluorescence Imaging
- Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 4
- States / cities
- Irvine, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Squamous Cell Carcinoma, Pharyngocutaneous Fistula
- Interventions
- Removal of pharyngeal mucosa with decreased perfusion will be performed, SPY-PHI, ICG (Indocyanine Green)
- Procedure · Device · Drug
- Lead sponsor
- Matthew Spector
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Trauma Injury
- Interventions
- Immunofluorescence Imaging
- Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Breast Cancer
- Interventions
- SPY Elite Imaging, Indocyanine Green, Isosulfan blue, 99technetium-sulfur colloid radiolabel
- Device · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
- Interventions
- ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
- Conditions
- Benign Neoplasm, Malignant Neoplasm
- Interventions
- Indocyanine green, SPY-PHI
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Peripheral Vascular Disease
- Interventions
- SPY Imaging, ICG dye (0.2 - 0.5 mg/kg), SPY Imaging
- Device
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Vulva Cancer
- Interventions
- Indocyanine green
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Rectal Cancer, Rectosigmoid Cancer
- Interventions
- PINPOINT, SPY Elite
- Device
- Lead sponsor
- Novadaq Technologies ULC, now a part of Stryker
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 24
- States / cities
- Concord, California • Los Angeles, California • Orange, California + 18 more
- Conditions
- Recurrent Melanoma
- Interventions
- Indocyanine green solution, Isosulfan blue (ISB), Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)
- Drug · Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Burn Wound
- Interventions
- Indocyanine green (ICG), Clinical Fluorescence Imaging Device
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Achilles Tendon Repairs/Reconstructions, Pilon Fracture of Tibia, Tibial Plateau Fracture, Ankle Fracture (Bimalleolar Equivalent, Bimalleolar, or Trimalleolar), Calcaneus Fractures, Talus Fracture, Wound Infection Deep, Wound Infection Post-Traumatic, Wound Dehiscence, Surgical
- Interventions
- Nitroglycerin Ointment 2%
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland